5AAU

Optimization of a novel binding motif to to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H- pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.9 Å
  • R-Value Free: 0.226 
  • R-Value Work: 0.173 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-Fluoro-2-Methylpropyl)-3-Methyl-2, 3,4,9-Tetrahydro-1H-Pyrido[3,4-B]Indol-1-Yl)Phenyl)Acrylic Acid (Azd9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

De Savi, C.Bradbury, R.H.Rabow, A.A.Norman, R.A.De Almeida, C.Andrews, D.M.Ballard, P.Buttar, D.Callis, R.Currie, G.S.Davies, C.Donald, C.Feron, L.Hayter, B.R.Hussain, S.Karoutchi, G.Lamont, S.Macfaul, P.A.Moss, T.A.Pearson, S.Tonge, M.Walker, G.Weir, H.Wilson, Z.

(2015) J.Med.Chem. 58: 8128

  • DOI: 10.1021/acs.jmedchem.5b00984
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equivalent potency and preclinical pharmacology to the intramuscular SERD fulvestrant is described. A directed screen identified the 1-aryl-2,3,4,9-tetrahyd ...

    The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equivalent potency and preclinical pharmacology to the intramuscular SERD fulvestrant is described. A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand. Aided by crystal structures of novel ligands bound to an ER construct, medicinal chemistry iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clinical candidate with high oral bioavailability across preclinical species that is currently being evaluated in phase I clinical trials for the treatment of advanced estrogen receptor (ER) positive breast cancer.


    Related Citations: 
    • Azd9496: An Oral Estrogen Receptor Inhibitor that Blocks the Growth of Er-Positive and Esr1-Mutant Breast Tumors in Preclinical Models.
      Weir, H.M.,Bradbury, R.H.,Lawson, M.,Rabow, A.A.,Buttar, D.,Callis, R.J.,Curwen, J.O.,De Almeida, C.,Ballard, P.,Hulse, M.,Donald, C.S.,Feron, L.J.L.,Karoutchi, G.,Macfaul, P.,Moss, T.,Norman, R.A.,Pearson, S.E.,Tonge, M.,Davies, G.,Walker, G.E.,Wilson, Z.,Rowlinson, R.,Powell, S.,Sadler, C.,Richmond, G.,Ladd, B.,Pazolli, E.,Mazzola, A.M.,D'Cruz, C.,De Savi, C.
      (2016) Cancer Res. 76: 3307


    Organizational Affiliation

    Oncology iMed, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.,Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K.,Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
ESTROGEN RECEPTOR
A, B
252Homo sapiensMutation(s): 3 
Gene Names: ESR1 (ESR, NR3A1)
Find proteins for P03372 (Homo sapiens)
Go to Gene View: ESR1
Go to UniProtKB:  P03372
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
XBR
Query on XBR

Download SDF File 
Download CCD File 
A, B
3-(1-(4-Chlorophenyl)-3,4-dihydro-1H-pyrido(3,4-b)indol-2(9H)-yl)propanoic acid
C20 H19 Cl N2 O2
LVUWGHOKMIGPFO-HXUWFJFHSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
XBRIC50: 13800 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.9 Å
  • R-Value Free: 0.226 
  • R-Value Work: 0.173 
  • Space Group: C 1 2 1
Unit Cell:
Length (Å)Angle (°)
a = 106.407α = 90.00
b = 51.396β = 93.66
c = 85.181γ = 90.00
Software Package:
Software NamePurpose
AMoREphasing
MOSFLMdata reduction
REFMACrefinement
SCALAdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Revision History 

  • Version 1.0: 2015-10-14
    Type: Initial release
  • Version 1.1: 2015-11-04
    Type: Database references
  • Version 1.2: 2016-10-12
    Type: Database references